581 related articles for article (PubMed ID: 17326127)
1. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
3. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer.
Cai M; Onoda K; Takao M; Kyoko IY; Shimpo H; Yoshida T; Yada I
Clin Cancer Res; 2002 Apr; 8(4):1152-6. PubMed ID: 11948127
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
[TBL] [Abstract][Full Text] [Related]
6. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
9. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
10. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
11. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence.
Hung JJ; Hsu WH; Hsieh CC; Huang BS; Huang MH; Liu JS; Wu YC
Thorax; 2009 Mar; 64(3):192-6. PubMed ID: 19252018
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
13. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of tenascin-C degradation fragment with recurrence and/or metastasis in early non-small-cell lung cancer].
Cai M; Xie ZT; Weng Y; Chang Q; Chang JH
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):518-21. PubMed ID: 18069632
[TBL] [Abstract][Full Text] [Related]
15. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.
Zheng S; Chang Y; Hodges KB; Sun Y; Ma X; Xue Y; Williamson SR; Lopez-Beltran A; Montironi R; Cheng L
Anticancer Res; 2010 Mar; 30(3):713-8. PubMed ID: 20392988
[TBL] [Abstract][Full Text] [Related]
16. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
[TBL] [Abstract][Full Text] [Related]
17. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
18. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.
Marchetti A; Bertacca G; Buttitta F; Chella A; Quattrocolo G; Angeletti CA; Bevilacqua G
Clin Cancer Res; 1999 Aug; 5(8):2077-81. PubMed ID: 10473089
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic impact of matrix metalloproteinases 2,9, and 11 in stromal cells stage I non-small cell lung cancer].
Drác P; Klein J; Tichý T; Kolek V; Skarda J
Cas Lek Cesk; 2007; 146(1):45-7. PubMed ID: 17310584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
